Long-term outcomes in patients with advanced coronary artery disease are better than expected

Death rates associated with patients with refractory angina, or chronic chest pain, are lower than previously considered; therefore, physicians should focus on relieving the chest pain symptoms and improving the quality of life in these patients according to an article published online this week in the European Heart Journal.

patients endure ongoing chest pain despite optimal medical management and for them, standard revascularization techniques, such as surgery or , is no longer an option. Traditionally, these are the patients with the most advanced , frequently referred to as "no-option patients."

"Importantly, this study describes the first long-term results from the largest and most contemporary follow-up of patients in a dedicated refractory angina clinic," says the study's first author Timothy D. Henry, MD, director of research at the Minneapolis Heart Institute Foundation. "Our results demonstrate that long-term mortality in patients with refractory angina is surprisingly low, below 4 percent per year."

The OPtions In Myocardial Ischemic Syndrome Therapy (OPTIMIST) program at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis was created for refractory angina patients in 1996 to develop new treatment options for this challenging patient population. This study reflects the long-term survival and predictors of mortality.

The study population consisted of 1,200 consecutive patients with either refractory and/or refractory angina, who were not candidates for traditional revascularization and referred for strategies from 1996 to present.

Overall, 241 patients of the 1,200 died during a median follow-up of 5.1 years. After an analysis, the researchers determined mortality was 3.9 percent at one year and 28.4 percent at nine years.

"Currently, data on the incidence and prevalence of refractory angina are scarce and mainly derived from registries," explains Henry.

In addition to the low overall mortality, the results indicated non-cardiac death in nearly 30 percent of patients and a low incidence of sudden cardiac death.

Improved secondary prevention strategies, evidence-based medical therapy and more advanced revascularization techniques all likely contributed to lower mortality, concluded Henry and his colleagues in the paper.

"Widespread and improved adherence to medical medications combined with aggressive lifestyle changes, such as diet, exercise and smoking cessation, has contributed to lower overall mortality in patients with coronary artery disease, and this includes the highest-risk patients with refractory angina," Henry notes.

Based on the findings, more than 70 percent of patients with refractory angina can expect to survive nine years from the time of diagnosis. Given these results, the researchers emphasized that therapeutic options for this growing population should therefore focus on chest pain relief and improved quality of life.

add to favorites email to friend print save as pdf

Related Stories

Chest pain prior to a heart attack can protect the heart

Feb 05, 2013

Patients who experience chest pain in the 24 hours preceding a heart attack, also called preinfarction angina, have smaller heart attacks and improved cardiac function in the contemporary cardiac stenting era, researchers ...

Cardiac shock wave therapy improves angina symptoms

Mar 30, 2012

(HealthDay) -- Cardiac shock wave therapy (CSWT) can significantly improve symptoms, ischemic threshold during exercise, and specific quality-of-life parameters for patients with chronic refractory angina ...

Chest pain: When conventional treatments don't work

Apr 19, 2012

Tens of thousands of Canadians seek emergency services and are referred for angiograms each year to investigate sources of chest pain. For approximately half a million Canadians, chronic chest pain – ...

Recommended for you

An autoimmune response may contribute to hypertension

43 minutes ago

High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease. Inflammation is thought to promote the development of high blood pressure, though it is not clear what triggers ...

Results of RIBS IV trial reported

Sep 16, 2014

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided superior late angiographic results ...

Results of DKCRUSH-VI trial reported

Sep 16, 2014

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial ...

Results of IVUS-CTO trial reported at TCT 2014

Sep 16, 2014

A new study found that intravascular ultrasound (IVUS) -guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided approach during percutaneous ...

User comments